Pressurized Metered Dose Inhalers Market Sees Momentum with COPD and Asthma Prevalence | AstraZeneca PLC, GlaxoSmithKline Inc., Merck & Co., Inc.

"The Global Pressurized Metered Dose Inhalers Market reached US$ 5,961.40 million in 2024 and is expected to reach US$ 9,212.15 billion by 2033, growing at a CAGR of 5.6% during the forecast period 2025-2033." As per DataM intelligence research report

Market growth opportunities(2025-2031):

The market is set to grow substantially due to the rising burden of respiratory illnesses like asthma and COPD across aging and urban populations. Increased adoption of pMDIs thanks to their portability and rapid therapeutic action is fueling demand. Emerging regions, particularly in Asia-Pacific, present robust growth potential owing to expanding healthcare access and rising awareness. Technological innovations such as smart inhalers and eco-friendly propellants are creating new market segments. These factors collectively establish a favorable environment for expansion and clinical acceptance.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/pressurized-metered-dose-inhalers-market?sp

Pressurized Metered Dose Inhalers Market: Recent Industry Developments

✅ In July 2025, AstraZeneca launched its new eco-friendly pMDI using HFO-1234ze propellant in Europe.It reduces carbon emissions by over 90% compared to traditional inhalers without compromising drug delivery.The launch aligns with the company's commitment to sustainable respiratory care.

✅ In June 2025, Teva Pharmaceuticals received FDA approval for a generic fluticasone-salmeterol pMDI.This affordable alternative aims to improve accessibility to combination asthma therapy in the U.S. market.Distribution began in early July through retail and hospital channels.

✅ In May 2025, Vectura partnered with Chiesi Group to co-develop a next-gen digital pMDI platform.The device will feature integrated dose tracking, usage alerts, and Bluetooth connectivity.Clinical trials are expected to begin in Q4 2025 targeting asthma and COPD patients.

✅ In April 2025, Glenmark Pharmaceuticals launched its Niveoli pMDI with a novel formulation for faster lung deposition.The new technology enhances bronchodilation in acute asthma episodes.The product is now available in key APAC and European markets.

✅ In March 2025, Catalent invested $60 million in expanding its U.K.-based pMDI filling and packaging facility.This expansion supports growing demand from branded and generic respiratory drug developers.It also enhances production of low-GWP (Global Warming Potential) inhalers.

Pressurized Metered Dose Inhalers Market: Drivers

The market is driven by the growing prevalence of respiratory diseases such as asthma and COPD, especially in densely populated urban areas and among older adults. The convenience, portability, and fast action of pressurized metered-dose inhalers make them a preferred drug delivery option. Rising awareness and diagnosis rates, along with improved access to healthcare infrastructure in emerging economies, support widespread adoption. Regulatory initiatives promoting greener inhaler technologies also contribute to industry momentum. Additionally, technological advancements are driving innovation in both functionality and environmental safety.

Pressurized Metered Dose Inhalers Market: Technological Advancements

✦ Development of low-global warming potential (GWP) propellants such as HFA‐152a and HFO‐1234ze significantly reduce environmental impact, supporting regulatory compliance and sustainability initiatives.
✦ Smart inhalers with sensors, Bluetooth connectivity, and dose tracking are improving treatment adherence and enabling remote monitoring by healthcare professionals.
✦ Introduction of breath-actuated and combination-therapy inhalers enhances accuracy and ease of use, especially for pediatric and elderly populations.
✦ AI-powered inhaler systems are enabling personalized therapy adjustments and early detection of respiratory condition exacerbations through real-time data analysis.
✦ Use of recyclable and biodegradable materials in inhaler manufacturing supports the shift toward environmentally sustainable production and lifecycle management.

Strategic Players Driving the Pressurized Metered Dose Inhalers Market Forward:

AstraZeneca PLC, GlaxoSmithKline Inc., Merck & Co., Inc., Lupin, Glenmark Pharmaceuticals Ltd., Cognita Labs, LLC, Bespak Limited, Healthgate PVT. LTD., Nemera, Getz Pharma (Pvt.) Ltd. and among others.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/pressurized-metered-dose-inhalers-market?sp

Segment Covered in the Pressurized Metered Dose Inhalers Market:

➥ By Type: Single Dose Pressurized Metered Dose Inhalers, Multi Dose Pressurized Metered Dose Inhalers
➥ By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Emphysema, Others
➥ By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Why Purchase the Report for Pressurized Metered Dose Inhalers Market?:

➠ Technology & Innovation: Tracks clinical trials and upcoming pharmaceutical advancements to stay ahead in product development.
➠ Market Positioning & Competitive Strategy: Analyzes product performance, market share, and competitor tactics for strategic decision-making.
➠ Real-World Evidence & Physician Insights: Incorporates patient data and physician behavior to align products with actual healthcare needs.
➠ Pricing & Market Access: Reviews reimbursement trends and access models to optimize product pricing and launch strategies.
➠ Regulatory & Industry Shifts: Covers policy changes, health system dynamics, and technology trends impacting market opportunities.
➠ Regional Growth & Expansion: Identifies high-growth markets and investment opportunities for geographic expansion.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=pressurized-metered-dose-inhalers-market?sp

Regional Analysis for Pressurized Metered Dose Inhalers Market:

North America leads the global market due to high disease prevalence, advanced healthcare infrastructure, and early adoption of new inhaler technologies. Europe follows closely, emphasizing sustainable inhaler propellants and strict regulatory standards. Asia-Pacific is projected to witness the fastest growth, supported by rising pollution-related respiratory conditions, expanding healthcare facilities, and increasing public health initiatives in developing nations.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.